There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Compugen (CGEN – Research Report) and AbbVie (ABBV – Research Report) with bullish sentiments.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Compugen (CGEN)
In a report released today, Leland Gershell from Oppenheimer reiterated a Buy rating on Compugen, with a price target of $4.00. The company’s shares closed last Monday at $2.24.
According to TipRanks.com, Gershell is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Compugen with a $8.50 average price target.
See Insiders’ Hot Stocks on TipRanks >>
AbbVie (ABBV)
J.P. Morgan analyst Chris Schott maintained a Buy rating on AbbVie on October 9 and set a price target of $250.00. The company’s shares closed last Monday at $230.30.
According to TipRanks.com, Schott is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AbbVie with a $241.89 average price target, a 5.2% upside from current levels. In a report issued on September 25, Leerink Partners also maintained a Buy rating on the stock with a $243.00 price target.
Read More on CGEN:
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)